-

ABBOTT LABORATORIES INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Continues to Investigate Abbott Laboratories’ Directors and Officers for Breach of Fiduciary Duties – ABT

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, reminds investors it is investigating whether certain directors and officers of Abbott Laboratories (“Abbott”) (NYSE: ABT) breached their fiduciary duties to Abbott and its shareholders. If you are an Abbott shareholder, you are encouraged to contact attorney Joe Pettigrew with Scott+Scott for additional information at (844) 818-6982 or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether members of Abbott’s board of directors or senior management failed to manage Abbott in an acceptable manner, in breach of their fiduciary duties to Abbott, and whether Abbott and its shareholders have suffered damages as a result.

On May 16, 2022, the U.S. filed a lawsuit and proposed consent decree against Abbott claiming that Abbott manufactured powdered infant formula under conditions and using practices that failed to comply with regulations designed to ensure the quality and safety of infant formula.

What You Can Do

If you are an Abbott shareholder, you may have legal claims against Abbott’s directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

Attorney Advertising

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
(844) 818-6982
jpettigrew@scott-scott.com

Scott+Scott Attorneys at Law LLP

NYSE:ABT

Release Versions

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
600 W. Broadway, Suite 3300, San Diego, CA 92101
(844) 818-6982
jpettigrew@scott-scott.com

More News From Scott+Scott Attorneys at Law LLP

THE ENSIGN GROUP, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates The Ensign Group, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ENSG

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of The Ensign Group, Inc. (NASDAQ: ENSG) failed to manage The Ensign Group in an acceptable manner, breaching their fiduciary duties to Ensign Group, and whether Ensign Group and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:On June 11, 2026, Muddy Waters Research...

CELSIUS HOLDINGS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Celsius Holdings, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CELH

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Celsius Holdings, Inc. (NASDAQ: CELH) failed to manage Celsius in an acceptable manner, breaching their fiduciary duties to Celsius, and whether Celsius and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On June 4, 2026, the Office of the Texas Attorney Genera...

ADMA BIOLOGICS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADMA

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) failed to manage ADMA Biologics in an acceptable manner, breaching their fiduciary duties to ADMA Biologics, and whether ADMA Biologics and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On March 24, 2026, Culper Research pu...
Back to Newsroom